Email:
info@smallcellovarian.org
Home
Resources
Expand Your Knowledge
About Small Cell Ovarian Cancer
Common Symptoms
Possible Oncologist Questions
Articles & Information
Helpful Links
Research
Biology of the Disease
Treatment Research
Reviews on SCCOHT
Case Reports
Clinical Trials
SCCOHT Networks
SCCOHT Consortium
Patient Registry
Physicians Network
Support Us
SCOCF Store
Note Cards
Lapel Pins
Bookmarks
Donate to SCOCF
In Honor Of
Bookmark Campaign
Team Events
Upcoming Events
Past Events
Create A SCOCF Team
Our Story
Contact Us
DONATE
Clinical Trials
The articles below are listed in chronological order, newest to oldest.
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
Study: The immune effects of seclidemstat in aggressive ovarian cancer striking young women
Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were wrong.
Prolonged survival of small cell ovarian cancer-hypercalcemic type (SCCOHT): Should radiotherapy play a larger role? (Filho et al., 2015)
Is cancer immunotherapy really a miracle cure?
Killing Cancer Through the Immune System
Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary. (Wallbillich et al., 2012)
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. (Pautier et al., 2007)
